Close Menu

NEW YORK — Solvd Health said on Monday that it has received CE marking for its genetic risk assessment test for opioid use disorder.

According to the Carlsbad, California-based company, the test analyzes a cheek swab sample for 15 genetic variants that have been implicated in the brain's reward pathway and can help guide the use of oral opioids for acute pain.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.